VistaGen (VTGN) Receives Positive FDA Feedback on Use of Liebowitz Social Anxiety Scale as Endpoint in Phase 3 of Fasedienol streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Vistagen plans to use the LSAS as the primary efficacy endpoint for a Phase 3 clinical study designed to evaluate fasedienol as a treatment for the overall control of symptoms of social anxiety. | March 30, 2023
FDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale as an Endpoint in Phase 3 Development of Fasedienol for Treatment of Social Anxiety. | March 30, 2023